Anvisa concluded on Tuesday (02/02) technical analysis of three in vitro diagnostic products for the commercial Zika virus. Two products using immunofluorescence methods for antibodies (IgG and IgM) related to Zika virus, Chikungunya and Dengue (subtypes 1, 2, 3 and 4) in a single test procedure combined. A third product using the polymerase chain reaction methodology (PCR) for the presence of the virus in the biological sample under study. Also the analyzes were completed by two other products for the presence of virus, Chikungunya and Dengue by PCR methodology.
The measure is in Resolution 301/2016, published Wednesday (3/2) in the Official Gazette (DOU).